Can we deconstruct cancer, one patient at a time?

Trends in Genetics

Volumn 29, Issue 1, 2013, Pages 6-10

  Blau, C Anthony ^a,b   Liakopoulou, Effie ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Partners in Personal Oncology   (United States)

Author keywords

Cancer; Learning loops; Longitudinal monitoring; N of 1; Omics; Personalized medicine; Research

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; BCR ABL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; STEM CELL FACTOR RECEPTOR;

CANCER PATIENT; CANCER RESEARCH; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL STROMAL TUMOR; GENOMICS; HUMAN; MELANOMA; NEOPLASM; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW;

BIOMEDICAL RESEARCH; COMMUNITY NETWORKS; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; METABOLOMICS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEOMICS; TIME FACTORS;

EID: 84871679432     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2012.09.004     Document Type: Review

References (29)

1. Curtis C., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
2. Gerlinger M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366:883-892.
3. Shibata D. Heterogeneity and tumor history. Science 2012, 336:304-305.
4. Marusyk A., et al. Intra-tumour heterogeneity: a looking glass for cancer?. Nat. Rev. Cancer 2012, 12:323-334.
5. Gerlinger M., Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br. J. Cancer 2010, 103:1139-1143.
6. McCarthy P.L., et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 2012, 366:1770-1781.
7. Sonneveld P., et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 Trial. J. Clin. Oncol. 2012, 30:2946-2955.
8. Harmon, A. (2010) New York Times 19 September, p. A1.
9. Chapman P.B., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364:2507-2516.
10. Comis R.L., et al. Physician-related factors involved in patient decisions to enroll onto cancer clinical trials. J. Oncol. Pract. 2009, 5:50-56.
11. Smith G.C., Pell J.P. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. Br. Med. J. 2003, 327:1459-1461.
12. Fox E.J., et al. Cancer genome sequencing: an interim analysis. Cancer Res. 2009, 69:4948-4950.
13. Welch J.S., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.
14. Hodis E., et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
15. Edelman L.B., et al. In silico models of cancer. Wiley Interdiscip. Rev. Syst. Biol. Med. 2010, 2:438-459.
16. Wu M., et al. Interaction between Ras(V12) and scribbled clones induces tumor growth and invasion. Nature 2010, 463:545-548.
17. Raaijmakers M., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464:852-857.
18. Ding L., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481:506-510.
19. Anderson K., et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469:356-361.
20. Leek J.T., et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat. Rev. Genet. 2010, 11:733-739.
21. Huang J., et al. Effects of ischemia on gene expression. J. Surg. Res. 2001, 99:222-227.
22. Jones S.J., et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol. 2010, 11:R82.
23. Kolata, G. (2012) New York Times 8 July, p. A1.
24. Kolata, G. (2012) New York Times 9 July, p. A1.
25. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
26. Chen R., et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012, 148:1293-1307.
27. del Sol A., et al. Diseases as network perturbations. Curr. Opin. Biotechnol. 2010, 21:566-571.
28. Goozner M. Duke scandal highlights need for genomics research criteria. J. Natl. Cancer Inst. 2011, 103:916-917.
29. Micheel C.M., et al. Evolution of Translational Omics: Lessons Learned and the Path Forward 2012, National Academies Press.